NCT06165276View on ClinicalTrials.gov

A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study

PHASE1CompletedINTERVENTIONAL

Enrollment

285

Participants

Timeline

Start Date

July 25, 2006

Primary Completion Date

August 27, 2008

Study Completion Date

August 27, 2008

Conditions

Meningococcal Immunization

Interventions

BIOLOGICAL

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).

Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

BIOLOGICAL

Meningococcal Group C-CRM197 Conjugate Vaccine

Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT06165276 - A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study | Biotech Hunter | Biotech Hunter